Company Profile
REGN insider trades (13 months) →Today's multi-factor rank: 133 of 466 · see the ranking
Market and Valuation
Price & Market
52-Week Range
Volume
Valuation Multiples
Dividends
Valuation Context
P/E vs sector (indicative)
Loading historical OHLCV database...
| Date | Open | High | Low | Close | Volume |
|---|
Financial Statements TTM (Trailing 12 Months)
Income Statement
Margins
Per Share
Balance Sheet & Liquidity
Cash Flows
Profitability
Historical Evolution (Last 4 Years)
Income Statement
Balance Sheet
Cash Flow
EPS and Earnings Per Share
Key EPS Metrics
Growth and Margins
Per Share
Cash Flows (TTM)
EPS Surprise History - Last 4 Quarters
Actual vs. Analyst Estimates · Green = beat expectations · Red = missed
| Quarter | Period | Actual EPS | Estimated EPS | Difference | Surprise % | Currency |
|---|
Ownership Structure
Ownership Distribution
Shares & Short Interest
Governance Score (1=Best, 10=Worst)
Top Institutional Holders
Position Change: ▲ Increased · ▼ Reduced · = Unchanged
| Organization | Report Date | % Shares | No. Shares | Value (USD) | Change % |
|---|
Top Mutual Funds
Position Change: ▲ Increased ▼ Decreased = Unchanged
| Fund | Report Date | % Shares | No. Shares | Value (USD) | Change % |
|---|
Recent Insider Trades
| Executive / Insider | Title | Date | Action | Shares |
|---|
Options Chain
CALLS
| Strike | Last | Bid | Ask | Vol. | O.I. | IV |
|---|
PUTS
| Strike | Last | Bid | Ask | Vol. | O.I. | IV |
|---|
Sentiment Metrics
Expected move
Regeneron Pharmaceuticals, Inc. (REGN) SEC filings: 10-K, 10-Q and 8-K
Direct links to financial reports filed with the SEC.
| Type | Date | Official link |
|---|---|---|
| N-PX | 2026-08-20 | View filing ↗ |
| 10-Q | 2026-07-30 | View filing ↗ |
| 8-K | 2026-07-06 | View filing ↗ |
| 8-K | 2026-06-17 | View filing ↗ |
| 8-K | 2026-04-29 | View filing ↗ |
| DEFA14A | 2026-04-24 | View filing ↗ |
| 8-K | 2026-04-08 | View filing ↗ |
| 10-K | 2026-02-04 | View filing ↗ |
| 8-K | 2026-01-30 | View filing ↗ |
| 8-K | 2026-01-12 | View filing ↗ |
Company and Executive Profile
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. Additionally, the company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies. The company was incorporated in 1988 and is based in Tarrytown, New York.
General Information
Key Executives
| Name | Title | Age | Total pay |
|---|---|---|---|
| Dr. Leonard S. Schleifer M.D., Ph.D. | Co-Founder, President, CEO & Co-Chairman | 72 | 7.28M |
| Dr. George D. Yancopoulos M.D., Ph.D. | Co-Founder, President, Chief Scientific Officer & Co-Chairman | 65 | 6.95M |
| Mr. Christopher R. Fenimore CPA | Executive VP of Finance & CFO | 54 | 1.49M |
| Mr. Joseph J. LaRosa J.D. | Executive VP, General Counsel & Secretary | 66 | 2.96M |
| Dr. Andrew J. Murphy Ph.D. | Executive VP of Research & Co-Chief Scientific Officer | 67 | 1.73M |
| Mr. Daniel P. Van Plew | Executive VP and GM of Industrial Operations & Product Supply | 52 | 2.03M |
| Mr. Rajesh Ahuja | Senior Vice President of Quality Assurance & Operations | - | - |
| Mr. Ryan Steinberger | Executive VP, Chief Digital & Technology Officer | - | - |
You have seen the engine room
Few finance sites let you get this far, and none we know of also shows you where its knowledge ends. If this way of working convinces you, the thing almost nobody catches in time can reach you by email: the big insider buys — executives and major shareholders putting in their own money — the same day they report them to the SEC, with the Form 4 linked. It takes three steps and none of them costs anything: create the account, confirm the email we send you, then switch the alert on in your profile (the icon at the top right). It starts off and it goes off again with the same click. Along the way all three are saved: your simulator portfolios, your personal portfolio and your Academy progress, synced across devices.